Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers—Early Experiences from Romania and Literature Review

Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers—Early Experiences from Romania and Literature Review

Prognosis in recurrent/metastatic head and neck squamous-cell carcinoma (HNSCC) refractory to platinum-based chemotherapy is poor, making therapy optimization a priority. Anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody Nivolumab was approved in such cases. We present the early e...

Full description

Bibliographic Details
Main Authors: Camil Ciprian Mireștean, Mihai Cosmin Stan, Michael Schenker, Constantin Volovăț, Simona Ruxandra Volovăț, Dragoș Teodor Petru Iancu, Roxana Irina Iancu, Florinel Bădulescu
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Diagnostics
Subjects:
head and neck squamous cell carcinoma (HNSCC)
Nivolumab
immunotherapy
neutrophil-to-lymphocyte ratio (NLR)
second primary malignancy (SPM)
platinum refractory
Online Access:https://www.mdpi.com/2075-4418/13/16/2620

Internet

https://www.mdpi.com/2075-4418/13/16/2620

Similar Items